Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Insomnia Therapeutics Market Poised To Hit $4.18 Billion By 2030 With A 5.5% CAGR
The insomnia therapeutics market size has seen robust expansion in recent years. It is anticipated to increase from $3.2 billion in 2025 to $3.38 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historic period growth can be linked to the escalating prevalence of sleep disorders, amplified stress and lifestyle-associated insomnia, the extensive use of prescription sleep aids, broadened retail pharmacy access, and a growing understanding of sleep health.
The insomnia therapeutics market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $4.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. Contributing factors to this growth during the projected timeframe include the rise of digital sleep therapies, a growing inclination towards non-pharmacological interventions, an expanding elderly demographic, wider embrace of wearable sleep technology, and the broadening availability of telehealth solutions for insomnia management. Key trends foreseen in this period encompass the increasing acceptance of cognitive behavioral therapy for insomnia, a surging need for sleep medications that are not habit-forming, augmented utilization of orexin receptor antagonists, the spread of home-based sleep therapy options, and enhanced incorporation of sleep tracking into treatment regimens.
Get A Free Sample Report With In-Depth Market Insights:
Insomnia Therapeutics Market Growth Backed By Core Demand Fundamentals
Elevated stress levels and evolving lifestyles are expected to stimulate the growth of the insomnia therapeutics market. Stress levels and lifestyle changes denote the psychological and behavioral modifications in daily routines and responsibilities that lead to emotional strain and disrupted sleep patterns. The increase in stress levels and lifestyle changes is primarily driven by constant digital connectivity, which blurs work-life boundaries and limits time for adequate mental rest. Insomnia therapeutics plays a vital role by providing effective, evidence-based treatment solutions that assist in restoring healthy sleep patterns, alleviating sleep-related anxiety, and supporting mental well-being amidst modern stressors. For instance, in May 2024, according to the American Psychiatric Association (APA), a US-based organization of psychiatrists, the proportion of U.S. adults reporting increased anxiety rose from 32% in 2022 to 37% in 2023, reaching 43% in 2024. Therefore, the escalating stress levels and lifestyle changes are contributing to the expansion of the insomnia therapeutics market.
Insomnia Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?
The insomnia therapeutics market covered in this report is segmented –
1) By Treatment Type: Drugs, Medical Devices
2) By Formulation: Tablets, Capsules, Liquid Solutions, Patches
3) By Route Of Administration: Oral, Intravenous, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics, Wellness Centers
Subsegments:
1) By Drugs: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Other Drugs
2) By Medical Devices: Cognitive Behavioral Therapy Devices (CBT-I Devices), Polysomnography Devices, Sleep Tracking Devices, Neurostimulation Devices, Light Therapy Devices
Insomnia Therapeutics Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the insomnia therapeutics market are concentrating on developing advanced therapies, such as dual orexin receptor antagonists (DORAs), to deliver targeted treatment choices that feature reduced side effects and enhanced safety profiles. A dual orexin receptor antagonist (DORA) is a category of medication that functions by blocking both orexin-1 and orexin-2 receptors in the brain, thereby promoting sleep through the inhibition of the wakefulness signaling pathway; these are commonly utilized in the management of insomnia. For instance, in June 2023, Idorsia Pharmaceuticals Ltd., a Switzerland-based pharmaceutical firm, launched QUVIVIQ (daridorexant), a first-in-class dual orexin receptor antagonist (DORA) designed for the treatment of chronic insomnia disorder. This therapy is formulated to decrease nighttime wakefulness without disturbing natural sleep architecture, offering patients better sleep initiation, continuity, and improved daytime performance. Its approval represents a substantial stride in insomnia treatment, offering a targeted mechanism of action that differs from traditional sedative-hypnotics and addressing the existing demand for long-term, non-habit-forming therapeutic solutions.
Insomnia Therapeutics Market Leading Players And Competitive Positioning
Major companies operating in the insomnia therapeutics market are Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Astellas Pharma Inc., Acadia Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Idorsia Ltd., Minerva Neurosciences, Neurim Pharmaceuticals Ltd., Big Health, Cerêve Inc., Innovative Neurological Devices, Neurovalens, Electromedical Products International Inc., Pear Therapeutics, ResMed Inc.
View The Full Insomnia Therapeutics Market Report:
Insomnia Therapeutics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the insomnia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insomnia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
